Figure F-136 is titled “Change in CAPS for SSRIs Compared with Placebo – Mixed Trauma Population: Sensitivity analysis including studies with high risk of bias.” The figure displays a forest plot reporting the weighted mean difference in CAPS stratified by citalopram compared with placebo, fluoxetine compared with placebo, paroxetine compared with placebo, and sertraline compared with placebo. Patients treated with citalopram did not significantly improve over those treated with placebo (1 trial, weighted mean difference 7.98, 95% CI −10.07 to 26.03). SSRIs that had greater reductions in CAPS than placebo included fluoxetine (3 trials, weighted mean difference −5.89, 95% CI −10.04 to −1.64, I2 = 0.0%), paroxetine (4 trials, weighted mean difference −12.41, 95% CI −15.47 to −9.36, I2 = 0.0%), and sertraline 5 trials, (weighted mean difference −5.83, 95% CI −9.31 to −2.35, I2 = 0.0%). The overall analysis including high risk of bias studies continued to favor SSRIs (weighted mean difference −8.01, 95% CI −10.55 to −5.48, I2 = 30.4%).

Figure F-136Change in CAPS for SSRIs compared with placebo – mixed trauma population: Sensitivity analysis including studies with high risk of bias

Note: Marshall et al., 2007 was rated high risk of bias.

Timing of outcome assessment: 10 weeks (Tucker, 2003; Marshall, 2007), 12 weeks (Martenyi, 2007; Marshall, 2001; Tucker, 2001; Davidson, 2006; Brady, 2005; Davidson, 2001; Brady, 2000); 8 weeks (van der Kolk, 2007).

From: Appendix F, Meta-Analysis

Cover of Psychological and Pharmacological Treatments for Adults With Posttraumatic Stress Disorder (PTSD)
Psychological and Pharmacological Treatments for Adults With Posttraumatic Stress Disorder (PTSD) [Internet].
Comparative Effectiveness Reviews, No. 92.
Jonas DE, Cusack K, Forneris CA, et al.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.